Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$0.16 USD
0.00 (-0.87%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $0.16 0.00 (0.63%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -5.15 | -5.09 | -3.95 | -2.95 |
Depreciation/Amortization & Depletion | NA | 0.13 | 0.19 | 0.23 | 0.31 |
Net Change from Assets/Liabilities | NA | -1.69 | 3.35 | 1.38 | -1.56 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.57 | -2.70 | -1.04 | -0.40 |
Net Cash From Operating Activities | NA | -6.15 | -4.25 | -3.38 | -4.59 |
Property & Equipment | NA | -0.27 | -0.14 | -0.18 | -0.21 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.61 | 3.80 |
Investments | NA | 0.01 | 0.04 | -0.04 | 0.05 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.26 | -0.10 | 0.39 | 3.64 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 2.87 | 7.77 | 2.29 | 1.38 |
Issuance (Repayment) of Debt | NA | -0.12 | -0.47 | 0.83 | -0.35 |
Increase (Decrease) Short-Term Debt | NA | -0.26 | 0.09 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.19 | 0.00 |
Net Cash from Financing Activities | NA | 2.49 | 7.40 | 3.31 | 1.03 |
Effect of Exchange Rate Changes | NA | 0.35 | 0.13 | 0.21 | -0.08 |
Net Change In Cash & Equivalents | NA | -3.58 | 3.18 | 0.53 | 0.00 |
Cash at Beginning of Period | NA | 7.40 | 4.22 | 3.69 | 3.69 |
Cash at End of Period | NA | 3.82 | 7.40 | 4.22 | 3.69 |
Diluted Net EPS | NA | -1.52 | -1.92 | -1.97 | -1.99 |
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.77 | -2.90 | -1.42 | -5.15 |
Depreciation/Amortization & Depletion | NA | 0.14 | 0.09 | 0.05 | 0.13 |
Net Change from Assets/Liabilities | NA | 0.54 | 0.92 | 0.89 | -1.69 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.54 | 0.45 | 0.27 | 0.57 |
Net Cash From Operating Activities | NA | -2.55 | -1.45 | -0.22 | -6.15 |
Property & Equipment | NA | -0.02 | -0.02 | -0.02 | -0.27 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.01 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.02 | -0.02 | -0.02 | -0.26 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.45 | 0.00 | 0.00 | 2.87 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | -0.12 |
Increase (Decrease) Short-Term Debt | NA | -0.39 | -0.26 | -0.13 | -0.26 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.01 | -0.01 | -0.01 | 0.00 |
Net Cash from Financing Activities | NA | 1.05 | -0.26 | -0.14 | 2.49 |
Effect of Exchange Rate Changes | NA | 0.10 | 0.05 | 0.09 | 0.35 |
Net Change In Cash & Equivalents | NA | -1.41 | -1.68 | -0.28 | -3.58 |
Cash at Beginning of Period | NA | 3.82 | 3.82 | 3.82 | 7.40 |
Cash at End of Period | NA | 2.41 | 2.14 | 3.54 | 3.82 |
Diluted Net EPS | NA | -0.08 | -0.29 | -0.29 | -0.28 |